A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder.

Trial Profile

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Imagabalin (Primary)
  • Indications Generalised anxiety disorder
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Jul 2009 Actual patient number (468) added as reported by ClinicalTrials.gov.
    • 10 Mar 2009 Planned end date changed from 1 Feb 2011 to 1 Apr 2009 as reported by ClinicalTrials.gov.
    • 10 Mar 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top